UNSPSC 51292009: Escitalopram

This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent with the molecular formula C20H21FN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4O4S742ANY, chemically known as 5-isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-, (1s)- but generally known as escitalopram, which bears US NIH Compound Identifier 146570. European Medicines Agency schedules Escitalopram in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16425MIG.

UNSPSC 51292009 Escitalopram is a Commodity code that nominally designates a single pharmaceutical product, but the recent state and local solicitations tagged with this code show little alignment with escitalopram procurement itself. Instead, the opportunities posted under this code reflect broader pharmaceutical supply arrangements, including naloxone distribution, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and over-the-counter products. State and local governments use this code inconsistently across health departments, county health services, and state HHS agencies to solicit pharmaceutical supplies and pharmacy benefit management services. The issuing bodies include county health departments (Seminole County, Florida) and state HHS commissions (Texas HHS Commission, Minnesota Department of Administration), suggesting a mix of local health authorities and state-level procurement offices managing pharmaceutical inventories and benefit programs.

Recent activity spans Florida, Texas, and Minnesota. Seminole County posted IFB 60459723LAS on June 30, 2026, to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 (note: due-date discrepancy in source). The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription fulfillment capabilities for a Therapeutic Pharmacy Initiative, with no formal award timeline specified. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, released RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities including Oregon, with proposals due March 26, 2026, and awards effective July 1, 2026. The mismatch between the code's nominal scope and actual solicitation content suggests that state and local buyers are using this code as a catch-all for pharmaceutical procurement across multiple product categories and delivery models rather than escitalopram-specific acquisitions.